GSA Capital Partners’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-41,432
Closed -$1.23M 2172
2025
Q1
$1.23M Buy
+41,432
New +$1.58M 0.11% 246
2023
Q2
Sell
-98,214
Closed -$2.19M 1962
2023
Q1
$2.19M Buy
+98,214
New +$2.37M 0.22% 53
2022
Q4
Sell
-49,228
Closed -$817K 1917
2022
Q3
$817K Buy
+49,228
New +$1.11M 0.11% 250
2022
Q2
Sell
-10,913
Closed -$301K 1825
2022
Q1
$301K Buy
+10,913
New +$312K 0.04% 889
2020
Q2
Sell
-12,491
Closed -$304K 1132
2020
Q1
$304K Buy
+12,491
New +$314K 0.08% 479
2019
Q4
Sell
-11,624
Closed -$279K 1755
2019
Q3
$279K Sell
11,624
-46,271
-80% -$1.23M 0.04% 960
2019
Q2
$1.65M Buy
57,895
+17,344
+43% +$433K 0.18% 75
2019
Q1
$1.01M Sell
40,551
-31,049
-43% -$593K 0.1% 284
2018
Q4
$901K Buy
71,600
+39,600
+124% +$468K 0.1% 258
2018
Q3
$306K Buy
32,000
+13,700
+75% +$151K 0.02% 1313
2018
Q2
$171K Buy
+18,300
New +$129K 0.01% 1561
2017
Q4
Sell
-25,800
Closed -$226K 1829
2017
Q3
$226K Sell
25,800
-4,200
-14% -$34.2K 0.02% 1400
2017
Q2
$250K Buy
30,000
+10,700
+55% +$87.3K 0.02% 1389
2017
Q1
$177K Buy
19,300
+4,200
+28% +$34.4K 0.01% 1597
2016
Q4
$117K Buy
+15,100
New +$113K 0.01% 1669

Other funds holding VCYT

GSA Capital Partners's VCYT Position: Q2 2025 in Review

GSA Capital Partners sold out of Veracyte (VCYT) in Q2 2025, closing a stake of 41,432 shares — an estimated $1.23M sold.

GSA Capital Partners first reported a position in VCYT in Q4 2016 and held it in 15 quarters. The position peaked at $2.19M in Q1 2023. 278 funds tracked by Wall St. Rank hold VCYT as of Q2 2025.

  • GSA Capital Partners reported no remaining Veracyte position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 41,432 Veracyte shares in Q2 2025, an estimated $1.23M.
  • GSA Capital Partners first reported a position in Veracyte in Q4 2016 and held it in 15 quarters.
  • GSA Capital Partners's Veracyte position peaked at $2.19M in Q1 2023.
  • 278 funds tracked by Wall St. Rank held Veracyte as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.